Absci Corporation
Absci Corporation (ABSI) Stock Competitors & Peer Comparison
See (ABSI) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABSI | $2.88 | -5.12% | 430.1M | -3.14 | -$0.91 | N/A |
| VRTX | $452.90 | -2.07% | 114.7B | 29.46 | $15.33 | N/A |
| REGN | $740.80 | -2.40% | 77.3B | 17.96 | $41.44 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $685.18 | -2.95% | 42.4B | 35.03 | $19.55 | N/A |
| ALNY | $313.09 | -2.29% | 41.7B | 135.11 | $2.33 | N/A |
| INSM | $143.58 | -0.24% | 30.8B | -22.23 | -$6.42 | N/A |
| UTHR | $533.73 | -1.16% | 23.2B | 19.03 | $27.87 | N/A |
| BNTX | $88.02 | -7.22% | 22.6B | -16.70 | -$5.39 | N/A |
Stock Comparison
ABSI vs VRTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, VRTX has a market cap of 114.7B. Regarding current trading prices, ABSI is priced at $2.88, while VRTX trades at $452.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas VRTX's P/E ratio is 29.46. In terms of profitability, ABSI's ROE is -0.60%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ABSI is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check VRTX's competition here
ABSI vs REGN Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, REGN has a market cap of 77.3B. Regarding current trading prices, ABSI is priced at $2.88, while REGN trades at $740.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas REGN's P/E ratio is 17.96. In terms of profitability, ABSI's ROE is -0.60%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ABSI is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check REGN's competition here
ABSI vs VRNA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ABSI is priced at $2.88, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ABSI's ROE is -0.60%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, ABSI is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check VRNA's competition here
ABSI vs SGEN Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ABSI is priced at $2.88, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ABSI's ROE is -0.60%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ABSI is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check SGEN's competition here
ABSI vs ARGX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ARGX has a market cap of 42.4B. Regarding current trading prices, ABSI is priced at $2.88, while ARGX trades at $685.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ARGX's P/E ratio is 35.03. In terms of profitability, ABSI's ROE is -0.60%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, ABSI is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ARGX's competition here
ABSI vs ALNY Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ALNY has a market cap of 41.7B. Regarding current trading prices, ABSI is priced at $2.88, while ALNY trades at $313.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ALNY's P/E ratio is 135.11. In terms of profitability, ABSI's ROE is -0.60%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, ABSI is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ALNY's competition here
ABSI vs INSM Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, INSM has a market cap of 30.8B. Regarding current trading prices, ABSI is priced at $2.88, while INSM trades at $143.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas INSM's P/E ratio is -22.23. In terms of profitability, ABSI's ROE is -0.60%, compared to INSM's ROE of -1.68%. Regarding short-term risk, ABSI is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check INSM's competition here
ABSI vs UTHR Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, ABSI is priced at $2.88, while UTHR trades at $533.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas UTHR's P/E ratio is 19.03. In terms of profitability, ABSI's ROE is -0.60%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ABSI is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check UTHR's competition here
ABSI vs BNTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, ABSI is priced at $2.88, while BNTX trades at $88.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas BNTX's P/E ratio is -16.70. In terms of profitability, ABSI's ROE is -0.60%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, ABSI is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check BNTX's competition here
ABSI vs MRNA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MRNA has a market cap of 20.7B. Regarding current trading prices, ABSI is priced at $2.88, while MRNA trades at $52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MRNA's P/E ratio is -7.22. In terms of profitability, ABSI's ROE is -0.60%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ABSI is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MRNA's competition here
ABSI vs BGNE Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ABSI is priced at $2.88, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ABSI's ROE is -0.60%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, ABSI is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check BGNE's competition here
ABSI vs ROIV Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ROIV has a market cap of 19.9B. Regarding current trading prices, ABSI is priced at $2.88, while ROIV trades at $27.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ROIV's P/E ratio is -23.76. In terms of profitability, ABSI's ROE is -0.60%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, ABSI is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ROIV's competition here
ABSI vs RPRX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, RPRX has a market cap of 19.6B. Regarding current trading prices, ABSI is priced at $2.88, while RPRX trades at $45.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas RPRX's P/E ratio is 25.72. In terms of profitability, ABSI's ROE is -0.60%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ABSI is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check RPRX's competition here
ABSI vs RVMD Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, RVMD has a market cap of 19.4B. Regarding current trading prices, ABSI is priced at $2.88, while RVMD trades at $98.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas RVMD's P/E ratio is -16.49. In terms of profitability, ABSI's ROE is -0.60%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, ABSI is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check RVMD's competition here
ABSI vs DNA-WT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ABSI is priced at $2.88, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ABSI's ROE is -0.60%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, ABSI is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ABSI.Check DNA-WT's competition here
ABSI vs INCY Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, INCY has a market cap of 18.4B. Regarding current trading prices, ABSI is priced at $2.88, while INCY trades at $92.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas INCY's P/E ratio is 14.39. In terms of profitability, ABSI's ROE is -0.60%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ABSI is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check INCY's competition here
ABSI vs GMAB Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, GMAB has a market cap of 15.9B. Regarding current trading prices, ABSI is priced at $2.88, while GMAB trades at $25.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas GMAB's P/E ratio is 16.79. In terms of profitability, ABSI's ROE is -0.60%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, ABSI is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check GMAB's competition here
ABSI vs ASND Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ASND has a market cap of 14B. Regarding current trading prices, ABSI is priced at $2.88, while ASND trades at $223.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ASND's P/E ratio is -52.64. In terms of profitability, ABSI's ROE is -0.60%, compared to ASND's ROE of +1.28%. Regarding short-term risk, ABSI is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ASND's competition here
ABSI vs BBIO Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, BBIO has a market cap of 13.6B. Regarding current trading prices, ABSI is priced at $2.88, while BBIO trades at $69.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas BBIO's P/E ratio is -18.55. In terms of profitability, ABSI's ROE is -0.60%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, ABSI is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check BBIO's competition here
ABSI vs KRTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ABSI is priced at $2.88, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ABSI's ROE is -0.60%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ABSI is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check KRTX's competition here
ABSI vs IONS Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, IONS has a market cap of 11.8B. Regarding current trading prices, ABSI is priced at $2.88, while IONS trades at $71.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas IONS's P/E ratio is -30.11. In terms of profitability, ABSI's ROE is -0.60%, compared to IONS's ROE of -0.69%. Regarding short-term risk, ABSI is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check IONS's competition here
ABSI vs SMMT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, SMMT has a market cap of 11.6B. Regarding current trading prices, ABSI is priced at $2.88, while SMMT trades at $15.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas SMMT's P/E ratio is -10.83. In terms of profitability, ABSI's ROE is -0.60%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, ABSI is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check SMMT's competition here
ABSI vs RNAM Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ABSI is priced at $2.88, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ABSI's ROE is -0.60%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ABSI is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check RNAM's competition here
ABSI vs JAZZ Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, JAZZ has a market cap of 11.1B. Regarding current trading prices, ABSI is priced at $2.88, while JAZZ trades at $179.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas JAZZ's P/E ratio is -30.90. In terms of profitability, ABSI's ROE is -0.60%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, ABSI is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check JAZZ's competition here
ABSI vs EXEL Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, EXEL has a market cap of 11.1B. Regarding current trading prices, ABSI is priced at $2.88, while EXEL trades at $41.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas EXEL's P/E ratio is 14.84. In terms of profitability, ABSI's ROE is -0.60%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, ABSI is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check EXEL's competition here
ABSI vs BMRN Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, ABSI is priced at $2.88, while BMRN trades at $55.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas BMRN's P/E ratio is 30.79. In terms of profitability, ABSI's ROE is -0.60%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, ABSI is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check BMRN's competition here
ABSI vs MDGL Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, ABSI is priced at $2.88, while MDGL trades at $446.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MDGL's P/E ratio is -34.45. In terms of profitability, ABSI's ROE is -0.60%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, ABSI is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MDGL's competition here
ABSI vs RXDX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ABSI is priced at $2.88, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ABSI's ROE is -0.60%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ABSI is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check RXDX's competition here
ABSI vs IBRX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, ABSI is priced at $2.88, while IBRX trades at $8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas IBRX's P/E ratio is -22.53. In terms of profitability, ABSI's ROE is -0.60%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, ABSI is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABSI.Check IBRX's competition here
ABSI vs IMGN Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ABSI is priced at $2.88, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ABSI's ROE is -0.60%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ABSI is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check IMGN's competition here
ABSI vs BPMC Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ABSI is priced at $2.88, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ABSI's ROE is -0.60%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, ABSI is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check BPMC's competition here
ABSI vs CERE Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ABSI is priced at $2.88, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CERE's P/E ratio is -16.47. In terms of profitability, ABSI's ROE is -0.60%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ABSI is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CERE's competition here
ABSI vs ABVX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ABVX has a market cap of 8.1B. Regarding current trading prices, ABSI is priced at $2.88, while ABVX trades at $122.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ABVX's P/E ratio is -24.41. In terms of profitability, ABSI's ROE is -0.60%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, ABSI is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ABVX's competition here
ABSI vs AXSM Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, AXSM has a market cap of 8.1B. Regarding current trading prices, ABSI is priced at $2.88, while AXSM trades at $158.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas AXSM's P/E ratio is -43.02. In terms of profitability, ABSI's ROE is -0.60%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, ABSI is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check AXSM's competition here
ABSI vs TECH Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, TECH has a market cap of 7.9B. Regarding current trading prices, ABSI is priced at $2.88, while TECH trades at $51.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas TECH's P/E ratio is 95.87. In terms of profitability, ABSI's ROE is -0.60%, compared to TECH's ROE of +0.04%. Regarding short-term risk, ABSI is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check TECH's competition here
ABSI vs ARWR Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ARWR has a market cap of 7.9B. Regarding current trading prices, ABSI is priced at $2.88, while ARWR trades at $56.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ARWR's P/E ratio is 35.44. In terms of profitability, ABSI's ROE is -0.60%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, ABSI is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ARWR's competition here
ABSI vs PCVX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, ABSI is priced at $2.88, while PCVX trades at $53.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas PCVX's P/E ratio is -9.64. In terms of profitability, ABSI's ROE is -0.60%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, ABSI is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check PCVX's competition here
ABSI vs CYTK Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CYTK has a market cap of 7.7B. Regarding current trading prices, ABSI is priced at $2.88, while CYTK trades at $62.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CYTK's P/E ratio is -9.51. In terms of profitability, ABSI's ROE is -0.60%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, ABSI is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CYTK's competition here
ABSI vs HALO Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, ABSI is priced at $2.88, while HALO trades at $64.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas HALO's P/E ratio is 24.86. In terms of profitability, ABSI's ROE is -0.60%, compared to HALO's ROE of +0.93%. Regarding short-term risk, ABSI is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check HALO's competition here
ABSI vs MTSR Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ABSI is priced at $2.88, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ABSI's ROE is -0.60%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ABSI is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MTSR's competition here
ABSI vs KRYS Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, KRYS has a market cap of 7.3B. Regarding current trading prices, ABSI is priced at $2.88, while KRYS trades at $254.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas KRYS's P/E ratio is 36.67. In terms of profitability, ABSI's ROE is -0.60%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ABSI is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check KRYS's competition here
ABSI vs NUVL Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, NUVL has a market cap of 7.1B. Regarding current trading prices, ABSI is priced at $2.88, while NUVL trades at $97.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas NUVL's P/E ratio is -16.65. In terms of profitability, ABSI's ROE is -0.60%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, ABSI is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check NUVL's competition here
ABSI vs MRUS Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ABSI is priced at $2.88, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ABSI's ROE is -0.60%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ABSI is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MRUS's competition here
ABSI vs ACLX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ABSI is priced at $2.88, while ACLX trades at $114.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ACLX's P/E ratio is -28.14. In terms of profitability, ABSI's ROE is -0.60%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ABSI is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ACLX's competition here
ABSI vs RETA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ABSI is priced at $2.88, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas RETA's P/E ratio is -66.29. In terms of profitability, ABSI's ROE is -0.60%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ABSI is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check RETA's competition here
ABSI vs KYMR Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, ABSI is priced at $2.88, while KYMR trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas KYMR's P/E ratio is -21.45. In terms of profitability, ABSI's ROE is -0.60%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, ABSI is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check KYMR's competition here
ABSI vs BLTE Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, ABSI is priced at $2.88, while BLTE trades at $160.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas BLTE's P/E ratio is -69.54. In terms of profitability, ABSI's ROE is -0.60%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, ABSI is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check BLTE's competition here
ABSI vs PTGX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, PTGX has a market cap of 6.2B. Regarding current trading prices, ABSI is priced at $2.88, while PTGX trades at $100.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas PTGX's P/E ratio is -47.36. In terms of profitability, ABSI's ROE is -0.60%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, ABSI is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check PTGX's competition here
ABSI vs PRAX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, PRAX has a market cap of 6.1B. Regarding current trading prices, ABSI is priced at $2.88, while PRAX trades at $289.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas PRAX's P/E ratio is -21.42. In terms of profitability, ABSI's ROE is -0.60%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, ABSI is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check PRAX's competition here
ABSI vs RYTM Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, ABSI is priced at $2.88, while RYTM trades at $85.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas RYTM's P/E ratio is -27.61. In terms of profitability, ABSI's ROE is -0.60%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, ABSI is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check RYTM's competition here
ABSI vs CDTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ABSI is priced at $2.88, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ABSI's ROE is -0.60%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ABSI is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CDTX's competition here
ABSI vs COGT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, ABSI is priced at $2.88, while COGT trades at $34.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas COGT's P/E ratio is -15.91. In terms of profitability, ABSI's ROE is -0.60%, compared to COGT's ROE of -1.00%. Regarding short-term risk, ABSI is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check COGT's competition here
ABSI vs PTCT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, ABSI is priced at $2.88, while PTCT trades at $66.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas PTCT's P/E ratio is 7.81. In terms of profitability, ABSI's ROE is -0.60%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, ABSI is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check PTCT's competition here
ABSI vs ABCM Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ABSI is priced at $2.88, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ABSI's ROE is -0.60%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ABSI is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ABCM's competition here
ABSI vs ISEE Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ABSI is priced at $2.88, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ABSI's ROE is -0.60%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ABSI is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ISEE's competition here
ABSI vs CGON Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, ABSI is priced at $2.88, while CGON trades at $63.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CGON's P/E ratio is -30.99. In terms of profitability, ABSI's ROE is -0.60%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ABSI is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CGON's competition here
ABSI vs FBIOX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, ABSI is priced at $2.88, while FBIOX trades at $24.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ABSI's ROE is -0.60%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ABSI is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check FBIOX's competition here
ABSI vs CAI Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, ABSI is priced at $2.88, while CAI trades at $18.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CAI's P/E ratio is -5.74. In terms of profitability, ABSI's ROE is -0.60%, compared to CAI's ROE of +0.25%. Regarding short-term risk, ABSI is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CAI's competition here
ABSI vs CELC Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CELC has a market cap of 5.2B. Regarding current trading prices, ABSI is priced at $2.88, while CELC trades at $111.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CELC's P/E ratio is -30.57. In terms of profitability, ABSI's ROE is -0.60%, compared to CELC's ROE of -1.79%. Regarding short-term risk, ABSI is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CELC's competition here
ABSI vs IMVT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, IMVT has a market cap of 4.8B. Regarding current trading prices, ABSI is priced at $2.88, while IMVT trades at $23.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas IMVT's P/E ratio is -8.84. In terms of profitability, ABSI's ROE is -0.60%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, ABSI is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check IMVT's competition here
ABSI vs TGTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, TGTX has a market cap of 4.8B. Regarding current trading prices, ABSI is priced at $2.88, while TGTX trades at $30.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas TGTX's P/E ratio is 9.91. In terms of profitability, ABSI's ROE is -0.60%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, ABSI is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ABSI.Check TGTX's competition here
ABSI vs MIRM Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, ABSI is priced at $2.88, while MIRM trades at $91.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MIRM's P/E ratio is -195.02. In terms of profitability, ABSI's ROE is -0.60%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, ABSI is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MIRM's competition here
ABSI vs XENE Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, ABSI is priced at $2.88, while XENE trades at $54.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas XENE's P/E ratio is -12.63. In terms of profitability, ABSI's ROE is -0.60%, compared to XENE's ROE of -0.56%. Regarding short-term risk, ABSI is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check XENE's competition here
ABSI vs CRSP Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, ABSI is priced at $2.88, while CRSP trades at $47.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CRSP's P/E ratio is -7.37. In terms of profitability, ABSI's ROE is -0.60%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, ABSI is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CRSP's competition here
ABSI vs ALKS Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ALKS has a market cap of 4.5B. Regarding current trading prices, ABSI is priced at $2.88, while ALKS trades at $27.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ALKS's P/E ratio is 19.02. In terms of profitability, ABSI's ROE is -0.60%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, ABSI is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ALKS's competition here
ABSI vs FOLD Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ABSI is priced at $2.88, while FOLD trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas FOLD's P/E ratio is -159.67. In terms of profitability, ABSI's ROE is -0.60%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ABSI is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check FOLD's competition here
ABSI vs AKRO Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ABSI is priced at $2.88, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ABSI's ROE is -0.60%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ABSI is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check AKRO's competition here
ABSI vs ALPN Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ABSI is priced at $2.88, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ABSI's ROE is -0.60%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ABSI is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ALPN's competition here
ABSI vs TERN Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, TERN has a market cap of 4.3B. Regarding current trading prices, ABSI is priced at $2.88, while TERN trades at $48.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas TERN's P/E ratio is -46.84. In terms of profitability, ABSI's ROE is -0.60%, compared to TERN's ROE of -0.30%. Regarding short-term risk, ABSI is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for ABSI.Check TERN's competition here
ABSI vs OPT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ABSI is priced at $2.88, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas OPT's P/E ratio is -1.52. In terms of profitability, ABSI's ROE is -0.60%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ABSI is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check OPT's competition here
ABSI vs ERAS Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, ABSI is priced at $2.88, while ERAS trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ERAS's P/E ratio is -30.68. In terms of profitability, ABSI's ROE is -0.60%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, ABSI is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ERAS's competition here
ABSI vs LGND Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, LGND has a market cap of 4.2B. Regarding current trading prices, ABSI is priced at $2.88, while LGND trades at $208.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas LGND's P/E ratio is 34.18. In terms of profitability, ABSI's ROE is -0.60%, compared to LGND's ROE of +0.14%. Regarding short-term risk, ABSI is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check LGND's competition here
ABSI vs MRTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ABSI is priced at $2.88, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ABSI's ROE is -0.60%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ABSI is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MRTX's competition here
ABSI vs SRRK Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, SRRK has a market cap of 4.1B. Regarding current trading prices, ABSI is priced at $2.88, while SRRK trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas SRRK's P/E ratio is -12.09. In terms of profitability, ABSI's ROE is -0.60%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, ABSI is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check SRRK's competition here
ABSI vs VKTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, ABSI is priced at $2.88, while VKTX trades at $33.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas VKTX's P/E ratio is -10.52. In terms of profitability, ABSI's ROE is -0.60%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, ABSI is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check VKTX's competition here
ABSI vs CNTA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CNTA has a market cap of 3.9B. Regarding current trading prices, ABSI is priced at $2.88, while CNTA trades at $28.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CNTA's P/E ratio is -15.19. In terms of profitability, ABSI's ROE is -0.60%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, ABSI is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for ABSI.Check CNTA's competition here
ABSI vs CRNX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, ABSI is priced at $2.88, while CRNX trades at $35.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CRNX's P/E ratio is -7.28. In terms of profitability, ABSI's ROE is -0.60%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, ABSI is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CRNX's competition here
ABSI vs RYZB Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ABSI is priced at $2.88, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ABSI's ROE is -0.60%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ABSI is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check RYZB's competition here
ABSI vs CBAY Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ABSI is priced at $2.88, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ABSI's ROE is -0.60%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ABSI is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CBAY's competition here
ABSI vs APGE Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, APGE has a market cap of 3.7B. Regarding current trading prices, ABSI is priced at $2.88, while APGE trades at $67.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas APGE's P/E ratio is -15.82. In terms of profitability, ABSI's ROE is -0.60%, compared to APGE's ROE of -0.37%. Regarding short-term risk, ABSI is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check APGE's competition here
ABSI vs CORT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CORT has a market cap of 3.5B. Regarding current trading prices, ABSI is priced at $2.88, while CORT trades at $33.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CORT's P/E ratio is 40.61. In terms of profitability, ABSI's ROE is -0.60%, compared to CORT's ROE of +0.15%. Regarding short-term risk, ABSI is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CORT's competition here
ABSI vs ADMA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ADMA has a market cap of 3.5B. Regarding current trading prices, ABSI is priced at $2.88, while ADMA trades at $14.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ADMA's P/E ratio is 24.78. In terms of profitability, ABSI's ROE is -0.60%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, ABSI is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ADMA's competition here
ABSI vs SWTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ABSI is priced at $2.88, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ABSI's ROE is -0.60%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, ABSI is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check SWTX's competition here
ABSI vs ACAD Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, ABSI is priced at $2.88, while ACAD trades at $20.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ACAD's P/E ratio is 8.83. In terms of profitability, ABSI's ROE is -0.60%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, ABSI is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ACAD's competition here
ABSI vs NAMS Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, NAMS has a market cap of 3.4B. Regarding current trading prices, ABSI is priced at $2.88, while NAMS trades at $29.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas NAMS's P/E ratio is -17.12. In terms of profitability, ABSI's ROE is -0.60%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, ABSI is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check NAMS's competition here
ABSI vs KNSA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, ABSI is priced at $2.88, while KNSA trades at $44.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas KNSA's P/E ratio is 60.20. In terms of profitability, ABSI's ROE is -0.60%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, ABSI is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check KNSA's competition here
ABSI vs LQDA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, LQDA has a market cap of 3.2B. Regarding current trading prices, ABSI is priced at $2.88, while LQDA trades at $36.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas LQDA's P/E ratio is -45.79. In terms of profitability, ABSI's ROE is -0.60%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, ABSI is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check LQDA's competition here
ABSI vs EWTX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, ABSI is priced at $2.88, while EWTX trades at $29.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas EWTX's P/E ratio is -18.21. In terms of profitability, ABSI's ROE is -0.60%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, ABSI is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check EWTX's competition here
ABSI vs DNLI Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, ABSI is priced at $2.88, while DNLI trades at $19.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas DNLI's P/E ratio is -6.75. In terms of profitability, ABSI's ROE is -0.60%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, ABSI is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ABSI.Check DNLI's competition here
ABSI vs DYN Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, DYN has a market cap of 3B. Regarding current trading prices, ABSI is priced at $2.88, while DYN trades at $17.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas DYN's P/E ratio is -5.21. In terms of profitability, ABSI's ROE is -0.60%, compared to DYN's ROE of -0.61%. Regarding short-term risk, ABSI is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check DYN's competition here
ABSI vs GPCR Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, GPCR has a market cap of 3B. Regarding current trading prices, ABSI is priced at $2.88, while GPCR trades at $51.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas GPCR's P/E ratio is -20.51. In terms of profitability, ABSI's ROE is -0.60%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, ABSI is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check GPCR's competition here
ABSI vs IDYA Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, ABSI is priced at $2.88, while IDYA trades at $32.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas IDYA's P/E ratio is -26.02. In terms of profitability, ABSI's ROE is -0.60%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, ABSI is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check IDYA's competition here
ABSI vs TARS Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, TARS has a market cap of 2.9B. Regarding current trading prices, ABSI is priced at $2.88, while TARS trades at $67.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas TARS's P/E ratio is -42.92. In terms of profitability, ABSI's ROE is -0.60%, compared to TARS's ROE of -0.20%. Regarding short-term risk, ABSI is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check TARS's competition here
ABSI vs MORF Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, ABSI is priced at $2.88, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MORF's P/E ratio is -14.88. In terms of profitability, ABSI's ROE is -0.60%, compared to MORF's ROE of -0.29%. Regarding short-term risk, ABSI is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MORF's competition here
ABSI vs MOR Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, ABSI is priced at $2.88, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas MOR's P/E ratio is -12.64. In terms of profitability, ABSI's ROE is -0.60%, compared to MOR's ROE of -1.84%. Regarding short-term risk, ABSI is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check MOR's competition here
ABSI vs DNTH Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, DNTH has a market cap of 2.9B. Regarding current trading prices, ABSI is priced at $2.88, while DNTH trades at $77.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas DNTH's P/E ratio is -22.53. In terms of profitability, ABSI's ROE is -0.60%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, ABSI is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check DNTH's competition here
ABSI vs TLX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, TLX has a market cap of 2.8B. Regarding current trading prices, ABSI is priced at $2.88, while TLX trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas TLX's P/E ratio is -420.50. In terms of profitability, ABSI's ROE is -0.60%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ABSI is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check TLX's competition here
ABSI vs CPRX Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, CPRX has a market cap of 2.8B. Regarding current trading prices, ABSI is priced at $2.88, while CPRX trades at $22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas CPRX's P/E ratio is 13.58. In terms of profitability, ABSI's ROE is -0.60%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ABSI is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check CPRX's competition here
ABSI vs ARQT Comparison March 2026
ABSI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABSI stands at 430.1M. In comparison, ARQT has a market cap of 2.8B. Regarding current trading prices, ABSI is priced at $2.88, while ARQT trades at $21.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABSI currently has a P/E ratio of -3.14, whereas ARQT's P/E ratio is -171.08. In terms of profitability, ABSI's ROE is -0.60%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, ABSI is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for ABSI.Check ARQT's competition here